Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 133Squamous Cell Carcinoma of Head and Neck 75Lung Neoplasms 48Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 31Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 29Cholangiocarcinoma 29Neoplasms 24Esophageal Squamous Cell Carcinoma 24Carcinoma 24Neoplasm Metastasis 23Small Cell Lung Carcinoma 21Ovarian Neoplasms 21Carcinoma, Squamous Cell 20Colorectal Neoplasms 19Stomach Neoplasms 18Pancreatic Neoplasms 17Carcinoma, Transitional Cell 17Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Cisplatin × 1 year × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡